all countries, survivor's post
When someone is battling cancer, they are usually overwhelmed and a thoughtful, useful gift can make a big difference in their daily life or comfort level. I came up with a series of lists because I realized that a lot of people are unsure of what to give or do for a...
all countries, coronavirus, COVID-19
Pseudomyxoma Survivor has received a number of inquiries as to whether people with a diagnosis of pseudomyxoma peritonei (PMP) or appendix cancer should have a COVID-19 vaccination. There is no evidence to support that people with rare diseases should avoid...
all countries, CRS&HIPEC, research, Treatment
Pseudomyxoma peritonei (PMP) is a rare malignant disease characterized by the progressive and multifocal accumulation of abundant mucinous tumour tissue in the peritoneal cavity. It is generally associated with a perforated epithelial neoplasm of the appendix. The...
all countries, Trustees, Volunteering
Pseudomyxoma Survivor provides a support network for those affected by pseudomyxoma peritonei (PMP) and appendix cancers. We do this through many ways including our website, our support group, our 1:1 buddy system, family grant scheme, raising awareness and keeping...
all countries, coronavirus, COVID-19, patient advocacy, UK
Pseudomyxoma Survivor is immensely proud to be a member of Cancer52. Cancer52 represents predominantly small patient support group cancer charities such as ourselves and by coming together, we aim to promote improved diagnosis, treatment and support for those affected...
all countries, patient advocacy, The Christie
All ready for tomorrow’s trip to The Christie. A little something for each of the staff that help to look after Pseudomyxoma...
all countries, raising awareness, specialist, Treatment Centres
Our first box of Christmas goodies is going out tomorrow – our way of saying “thank you” to the amazing hospital consultants and staff that have helped look after Pseudomyxoma Survivors on the wards. As always, a huge thanks also to our fundraisers...
Recent Comments